Skip to main content
. 2023 Oct 6;11:1236527. doi: 10.3389/fpubh.2023.1236527

Table 2.

Association between qualitative variables and median scores for each SF-36 domain 1 year after hospital admission for COVID-19.

Qualitative variables Comparison of median scores and IQR (in brackets) in each SF-36 domain, according to dichotomous explanatory variables (no/yes; Mann–Whitney U test)
Physical functioning Physical role Bodily pain General health Vitality Social functioning Emotional role Mental health
No Yes p No Yes p No Yes p No Yes p No Yes p No Yes p No Yes p No Yes p
Medical history
Female 95 (80–100) 80 (49–95) <0.001 100 (100–100) 100 (0–100) <0.001 100 (80–100) 70 (45–100) <0.001 70 (60–80) 55 (35–70) <0.001 70 (55–85) 55 (35–75) <0.001 100 (88–100) 100 (62–100) <0.001 100 (100–100) 100 (67–100) <0.001 80 (64–88) 64 (48–80) <0.001
Smoker/ex-smoker 90 (70–100) 95 (70–100) 0.600 100 (75–100) 100 (75–100) 0.700 90 (60–100) 90 (67–100) 0.910 65 (45–80) 65 (45–75) 0.810 65 (45–80) 65 (45–80) 0.960 100 (75–100) 100 (87–100) 0.880 100 (100–100) 100 (100–100) 0.071 72 (60–88) 76 (60–84) 0.670
Hypertension 95 (75–100) 90 (57–100) <0.001 100 (75–100) 100 (75–100) 0.870 100 (67–100) 90 (57–100) 0.610 70 (45–80) 65 (45–75) 0.082 70 (45–80) 65 (45–80) 0.710 100 (87–100) 100 (87–100) 0.540 100 (100–100) 100 (100–100) 0.860 72 (60–84) 76 (60–88) 0.150
Dyslipidemia 95 (70–100) 90 (55–100) 0.044 100 (78–100) 100 (75–100) 0.300 90 (67–100) 90 (57–100) 0.980 65 (45–80) 65 (45–75) 0.180 65 (45–80) 67 (45–80) 0.950 100 (87–100) 100 (75–100) 0.790 100 (100–100) 100 (100–100) 0.920 72 (59–84) 76 (60–88) 0.270
Anxiety 95 (70–100) 77 (55–95) 0.001 100 (75–100) 100 (0–100) 0.110 100 (67–100) 80 (58–100) 0.130 70 (45–80) 60 (36–70) 0.006 70 (45–84) 50 (35–65) <0.001 100 (87–100) 88 (63–100) 0.015 100 (100–100) 100 (33–100) 0.003 76 (60–88) 64 (53–79) <0.001
Depression 95 (70–100) 70 (55–90) 0.005 100 (75–100) 100 (75–100) 0.720 90 (67–100) 90 (60–100) 0.700 65 (45–80) 55 (30–75) 0.006 70 (45–80) 45 (30–65) 0.001 100 (87–100) 100 (38–100) 0.270 100 (100–100) 100 (67–100) 0.400 76 (60–88) 68 (56–84) 0.250
Fibromyalgia/chronic fatigue 95 (70–100) 40 (22–55) <0.001 100 (77–100) 0 (0–100) <0.001 100 (67–100) 45 (23–62) <0.001 65 (45–80) 30 (17–42) <0.001 70 (45–80) 30 (17–37) <0.001 100 (87–100) 63 (37–87) <0.001 100 (100–100) 33 (0–100) 0.001 76 (60–88) 48 (42–66) <0.001
Obesity (BMI > 30 kg/m2) 95 (80–100) 80 (50–95) <0.001 100 (100–100) 100 (0–100) <0.001 100 (70–100) 80 (52–100) <0.001 70 (50–80) 60 (40–75) 0.001 70 (50–85) 60 (40–75) <0.001 100 (87–100) 100 (75–100) 0.010 100 (100–100) 100 (67–100) 0.015 76 (60–88) 72 (54–84) 0.027
Ischemic cardiopathy 95 (70–100) 75 (54–95) 0.040 100 (75–100) 100 (62–100) 0.560 95 (61–100) 80 (68–100) 0.340 65 (45–80) 47 (40–64) 0.037 65 (45–80) 70 (54–85) 0.450 100 (87–100) 100 (84–100) 0.570 100 (100–100) 100 (100–100) 0.600 72 (60–87) 82 (67–92) 0.140
Cardiac insufficiency 95 (70–100) 75 (10–95) 0.004 100 (75–100) 100 (87–100) 0.820 100 (67–100) 70 (54–100) 0.130 65 (45–80) 55 (40–65) 0.015 65 (45–80) 70 (57–82) 0.310 100 (87–100) 100 (81–100) 0.870 100 (100–100) 100 (100–100) 0.400 72 (58–84) 80 (66–92) 0.120
COPD 95 (70–100) 90 (57–95) 0.410 100 (75–100) 100 (87–100) 0.590 90 (67–100) 70 (21–90) 0.130 65 (45–80) 75 (37–82) 0.770 65 (45–80) 85 (47–95) 0.170 100 (87–100) 100 (81–100) 0.480 100 (100–100) 100 (100–100) 0.270 72 (60–88) 80 (56–84) 0.940
Chronic bronchitis 95 (70–100) 80 (59–99) 0.420 100 (75–100) 100 (25–100) 0.950 90 (67–100) 90 (34–100) 0.820 65 (45–80) 60 (46–74) 0.520 65 (45–80) 75 (52–84) 0.330 100 (87–100) 100 (81–100) 0.550 100 (100–100) 100 (100–100) 0.540 72 (60–88) 76 (61–83) 0.930
Asthma 95 (70–100) 47 (21–77) 0.023 100 (75–100) 0 (0–75) 0.012 90 (67–100) 34 (22–86) 0.064 65 (45–80) 25 (20–56) 0.020 65 (45–80) 20 (15–44) 0.008 100 (87–100) 63 (41–94) 0.060 100 (100–100) 50 (0–100) 0.084 75 (60–88) 54 (37–74) 0.110
Chronic kidney disease 95 (70–100) 70 (12–91) 0.006 100 (75–100) 100 (0–100) 0.280 90 (67–100) 70 (39–100) 0.270 65 (45–80) 47 (32–66) 0.040 65 (45–80) 55 (30–76) 0.240 100 (87–100) 100 (47–100) 0.400 100 (100–100) 100 (67–100) 0.420 73 (60–88) 70 (39–85) 0.320
Diabetes 95 (70–100) 90 (60–100) 0.240 100 (75–100) 100 (0–100) 0.450 90 (67–100) 100 (55–100) 0.750 65 (45–80) 65 (45–80) 0.600 65 (45–80) 65 (40–85) 0.580 100 (87–100) 100 (75–100) 0.930 100 (100–100) 100 (100–100) 0.580 75 (60–84) 72 (52–88) 0.870
Diabetes with target organ damage 95 (70–100) 75 (35–95) 0.044 100 (75–100) 100 (75–100) 0.560 100 (67–100) 68 (57–90) 0.110 65 (45–80) 45 (35–60) 0.039 65 (45–80) 65 (45–85) 0.890 100 (87–100) 100 (87–100) 0.690 100 (100–100) 100 (100–100) 0.418 72 (60–84) 84 (68–92) 0.140
Clinical outcomes
ARDS 95 (70–100) 90 (70–100) 0.830 100 (75–100) 100 (100–100) 0.310 90 (67–100) 100 (62–100) 0.620 65 (45–75) 65 (50–80) 0.780 65 (40–80) 70 (50–85) 0.054 100 (75–100) 100 (87–100) 0.580 100 (100–100) 100 (100–100) 0.350 72 (56–84) 76 (62–88) 0.091
ICU admission 95 (70–100) 95 (66–100) 0.950 100 (75–100) 100 (75–100) 0.710 95 (67–100) 90 (57–100) 0.500 65 (45–80) 70 (50–80) 0.230 65 (45–80) 70 (46–89) 0.041 100 (87–100) 100 (75–100) 0.370 100 (100–100) 100 (67–100) 0.054 74 (60–85) 73 (60–88) 0.540
Helmet-CPAP 95 (70–100) 95 (65–100) 0.990 100 (75–100) 100 (75–100) 0.620 100 (67–100) 90 (57–100) 0.370 65 (45–80) 70 (47–80) 0.330 65 (45–80) 70 (45–85) 0.086 100 (87–100) 100 (75–100) 0.470 100 (100–100) 100 (67–100) 0.041 76 (60–86) 72 (58–88) 0.640
High-flow oxygen 95 (66–100) 95 (81–100) 0.300 100 (75–100) 100 (100–100) 0.170 90 (61–100) 100 (77–100) 0.260 65 (45–80) 70 (60–80) 0.161 65 (45–80) 70 (60–86) 0.035 100 (87–100) 100 (87–100) 0.980 100 (100–100) 100 (100–100) 0.360 72 (57–84) 80 (63–88) 0.210
Mechanical ventilation 95 (70–100) 90 (60–100) 0.730 100 (75–100) 100 (50–100) 0.950 90 (67–100) 80 (46–100) 0.250 65 (45–80) 70 (52–87) 0.500 65 (45–80) 75 (39–90) 0.370 100 (87–100) 87 (69–100) 0.140 100 (100–100) 100 (100–100) 0.880 72 (60–88) 80 (56–88) 0.720
Systemic corticosteroids during admission 90 (45–100) 95 (70–100) 0.170 100 (25–100) 100 (75–100) 0.210 80 (57–100) 100 (67–100) 0.023 62 (35–76) 65 (45–80) 0.330 60 (39–85) 70 (45–80) 0.340 100 (75–100) 100 (87–100) 0.061 100 (100–100) 100 (100–100) 0.820 76 (51–88) 72 (60–84) 0.980
SARS-CoV-2 vaccination after admission 95 (65–100) 95 (71–100) 0.960 100 (75–100) 100 (76–100) 0.670 90 (60–100) 90 (68–100) 0.200 70 (45–80) 65 (45–75) 0.410 70 (50–85) 70 (50–80) 0.360 100 (75–100) 100 (88–100) 0.450 100 (100–100) 100 (100–100) 0.820 80 (60–88) 75 (60–84) 0.180

ARDS, Acute respiratory distress syndrome; BMI, Body mass index; COPD, Chronic obstructive pulmonary disease; ICU, Intensive care unit; and SF-36, 36-item Short Form health survey.

Values in bold have reached statistical significance.